Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
DNA filed a Form 144 reporting proposed sales of Class A shares. The notice lists a proposed sale of 324 Class A shares tied to restricted stock vesting dated 04/16/2026. It also discloses recent reported sales by Steve Coen: 972 shares on 01/20/2026, 708 shares on 03/16/2026, and 33,171 shares on 04/13/2026, each with the corresponding proceeds shown in the filing.
DNA submitted a Rule 144 notice reporting proposed resales of Class A common stock. The notice lists sale entries by Austin Che on 02/04/2026 (2,200 shares), 03/11/2026 (2,200 shares) and 04/13/2026 (40,893 shares) with proceeds of $262,291.79 shown for the 04/13/2026 entry. The filing also records a restricted stock vesting date of 10/20/2022 and names Fidelity Brokerage Services LLC as a broker on the notice.
Ginkgo Bioworks Holdings, Inc. executive Steven P. Coen reported PSU vesting and related share activity. On April 10, 2026, he acquired a total of 73,921 shares of Class A Common Stock through the vesting and conversion of performance-based restricted stock units.
On April 13, 2026, he sold 33,171 shares at $6.414 per share solely to cover tax withholding obligations under a mandatory “sell to cover” mechanism, which the company’s equity plans permit and which is described as non-discretionary. After these transactions, he held 49,849 shares directly.
The PSUs were tied to cash flow reduction performance targets for the finance team and company-wide. One 45,755-PSU grant vested at 62% of its target, and a 67,991-PSU grant vested at 67%, as certified by the Compensation Committee.
Ginkgo Bioworks Holdings, Inc. major holder Canton Barry reported his spouse’s performance-based equity vesting and related tax sale. On April 9, 2026, 251,786 performance-based restricted stock units converted into an equal number of Class A shares at a $0.00 exercise price.
These PSUs came from a 375,800-unit grant tied to a company-wide cash flow reduction target for January 1, 2025 through December 31, 2025, with actual performance certified at 67% of target. On April 10, 2026, Barry’s spouse sold 124,727 Class A shares at $6.434 per share solely to cover tax withholding obligations under the issuer’s equity incentive plans, which the filing states were non-discretionary “sell to cover” transactions. After these transactions, 436,422 Class A shares were held indirectly through his spouse.
Ginkgo Bioworks Holdings director/officer Reshma P. Shetty exercised performance-based stock units and sold shares to cover taxes. On April 9, 2026, 251,786 performance-based restricted stock units vested and converted into Class A Common Stock based on a company-wide cash flow target achieved at 67% of goal.
These units came from a June 19, 2025 grant of 375,800 PSUs tied to cash flow performance for the period from January 1, 2025 to December 31, 2025. On April 10, 2026, 124,727 shares of Class A Common Stock were sold solely to satisfy tax withholding obligations under the company’s equity incentive plans through a required “sell to cover” transaction, which the disclosure states was not a discretionary trade. After these transactions, Shetty directly held 436,422 shares of Class A Common Stock.
DNA submitted a Form 144 notice listing 33,171 shares of Class A stock associated with a restricted stock vesting event dated 04/10/2026. The filing lists Fidelity Brokerage Services LLC as a broker and records prior dispositions by Steve Coen of 972 and 708 shares on 01/20/2026 and 03/16/2026, respectively.
DNA filed a Form 144 reporting a proposed sale of Class A shares and recent small dispositions. The filing lists 40,893 Class A shares tied to a proposed sale and records two past dispositions of 2,200 shares on 02/04/2026 and 03/11/2026. The broker listed is Fidelity Brokerage Services LLC.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Ginkgo Bioworks Holdings director and officer Jason R. Kelly reported PSU vesting and related share sales. On April 7 and 8, 2026, he exercised performance-based restricted stock units to receive a total of 425,898 shares of Class A Common Stock at a conversion price of $0.0000 per share.
Footnotes state that 206,782 of these shares were sold at prices of about $6.93 and $6.397 per share solely to cover tax withholding obligations in connection with the PSU vesting, under the company’s “sell to cover” provisions, and are not discretionary trades. After these transactions, he directly held 316,483 Class A shares.
The PSUs were part of a 635,670-unit grant dated June 19, 2025, tied to a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025, with actual performance certified at 67% and shares distributed on April 7 and 8, 2026.